Compare RAYMED LABS. with DIL LIMITED - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

RAYMED LABS vs FERMENTA BIOTECH - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    RAYMED LABS FERMENTA BIOTECH RAYMED LABS/
FERMENTA BIOTECH
 
P/E (TTM) x -5.4 28.3 - View Chart
P/BV x - 2.4 - View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 RAYMED LABS   FERMENTA BIOTECH
EQUITY SHARE DATA
    RAYMED LABS
Mar-20
FERMENTA BIOTECH
Mar-21
RAYMED LABS/
FERMENTA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3442 0.7%   
Low Rs1218 0.4%   
Sales per share (Unadj.) Rs0130.8 0.0%  
Earnings per share (Unadj.) Rs-0.114.7 -0.9%  
Cash flow per share (Unadj.) Rs-0.121.8 -0.5%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Avg Dividend yield %00.8 0.0%  
Book value per share (Unadj.) Rs-4.6120.8 -3.8%  
Shares outstanding (eoy) m4.2728.85 14.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio xNM2.5-  
Avg P/E ratio x-14.822.4 -66.1%  
P/CF ratio (eoy) x-16.615.1 -109.4%  
Price / Book Value ratio x-0.42.7 -15.2%  
Dividend payout %017.0 0.0%   
Avg Mkt Cap Rs m89,520 0.1%   
No. of employees `000NANA-   
Total wages/salary Rs m0582 0.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m03,773 0.0%  
Other income Rs m084 0.2%   
Total revenues Rs m03,857 0.0%   
Gross profit Rs m-1826 -0.1%  
Depreciation Rs m0203 0.0%   
Interest Rs m0190 0.0%   
Profit before tax Rs m-1516 -0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m091 0.0%   
Profit after tax Rs m-1425 -0.1%  
Gross profit margin %NM21.9- 
Effective tax rate %017.6 0.0%   
Net profit margin %NM11.3- 
BALANCE SHEET DATA
Current assets Rs m13,096 0.0%   
Current liabilities Rs m222,093 1.1%   
Net working cap to sales %NM26.6- 
Current ratio x01.5 2.7%  
Inventory Days DaysNM83- 
Debtors Days DaysNM658- 
Net fixed assets Rs m23,371 0.0%   
Share capital Rs m43144 29.6%   
"Free" reserves Rs m-633,342 -1.9%   
Net worth Rs m-203,486 -0.6%   
Long term debt Rs m01,104 0.0%   
Total assets Rs m36,468 0.0%  
Interest coverage xNM3.7-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x00.6 0.0%   
Return on assets %-21.79.5 -227.7%  
Return on equity %2.812.2 23.0%  
Return on capital %2.815.4 18.2%  
Exports to sales %NM0-  
Imports to sales %NM0-  
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m02,551 0.0%   
Fx outflow Rs m01,035 0.0%   
Net fx Rs m01,516 0.0%   
CASH FLOW
From Operations Rs m0626 0.0%  
From Investments Rs mNA-416 0.0%  
From Financial Activity Rs mNA-11 0.0%  
Net Cashflow Rs m0205 0.0%  

Share Holding

Indian Promoters % 28.4 59.4 47.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.0 0.0 9,600.0%  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 71.6 40.6 176.7%  
Shareholders   1,428 18,399 7.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare RAYMED LABS With:   BACIL PHARMA  ALEMBIC  SANDU PHARMA  GUFIC BIOSCIENCE  ALBERT DAVID  



Today's Market

Sensex Jumps 550 Points, Nifty Above 17,000; Metal & Banking Stocks Rally(10:30 am)

Asian stock markets are higher today as investors took heart from strong rebounds on Wall Street on hopes that the newest coronavirus variant will prove less virulent than earlier strains.

Related Views on News

FERMENTA BIOTECH 2020-21 Annual Report Analysis (Annual Result Update)

Oct 29, 2021 | Updated on Oct 29, 2021

Here's an analysis of the annual report of FERMENTA BIOTECH for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of FERMENTA BIOTECH. Also includes updates on the valuation of FERMENTA BIOTECH.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles(Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

RAYMED LABS SHARE PRICE


Dec 6, 2021 (Close)

TRACK RAYMED LABS

  • Track your investment in RAYMED LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RAYMED LABS 5-YR ANALYSIS

COMPARE RAYMED LABS WITH

MARKET STATS